• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Smoking cessation rates equivalent between most common pharmacotherapies

byDaniel FisherandMichael Milligan
January 26, 2016
in Chronic Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. No differences in smoking cessation rates were detected between patients who received nicotine patch monotherapy, combined nicotine patch and lozenge therapy, or varenicline, 6 months and 1 year after follow-up.

2. Both combination nicotine replacement therapy and varenicline were superior to nicotine patch monotherapy in reducing withdrawal symptoms.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Though the adverse effects of smoking are well-known, many patients still struggle to quit. Recent meta-analyses have suggested that combination nicotine replacement therapies (C-NRT) and varenicline may be more effective than nicotine patch monotherapies for smoking cessation. For a direct comparison, a randomized controlled trial examined the effectiveness of these three therapies combined with an intensive counselling program. At both 26 and 52 weeks after beginning treatment, there were no statistical differences in prolonged or 7-day abstinence between these therapies. In addition, smoking cessation was not statistically different between the three groups after stratifying smokers into high and low nicotine dependent groups. During the first week of quitting, there was a significant difference in withdrawal suppression, with the C-NRT and varenicline groups reporting less withdrawal symptoms than the nicotine monotherapy controls. This study highlights the difficulties in effective smoking cessation therapies and suggests that more rigorous pharmacotherapies may not greatly add to quitting success. However, while this study was well-designed and adequately powered, cessation rates of all therapies were lower than previous meta-analyses and only about 50% of patients were adherent across therapies.

Click to read the study, published today in JAMA

Relevant Reading: Treating Tobacco Use and Dependence: 2008 Update

In-Depth [randomized controlled trial]: This study enrolled 1086 patients (52% women) in Wisconsin who were willing to quit smoking. Notable exclusion criteria included prior suicide attempts, moderate to severe depression, hypertension of 200/100 mmHg or greater, use of bupropion, and prior hospitalization for cardiac disease or diabetes. Among recruited patients, 38.5% were prescribed varencicline, 38.5% C-NRT, and 23% nicotine patch monotherapy. All therapies included enrollment in an intensive counseling program. Follow-up data at 12 months was recorded for 84% of patients. There were no differences detected in the 7-day point-abstinence rates, which were confirmed with biochemical carbon monoxide testing at 26 and 52 weeks of treatment. The prolonged abstinence rates at 26 weeks were also not significant, with estimated cessation rates of 14.9%, 16.5%, and 15.4% for the nicotine patch, varenicline, and C-NRT, respectively. In a subgroup analysis, the time between waking and smoking was used as a corollary for dependence (less <30 min is more dependent while >30 min is less dependent). However, even when adjusting for dependence, no significant differences in cessation rates between therapies was found, nor were there interactions between dependence and treatment. At the end of the first week of treatment, both C-NRT and varencicline were associated with fewer withdrawal symptoms than nicotine patch monotherapy (C-NRT vs. patch mean difference 0.28, 95%CI 0.11–0.46; varenicline vs. patch mean difference 0.22, 95%CI 0.05–0.40), with no difference between the C-NRT and varencicline groups. At week 8, adherence rates were low; 45.2%, 49.3%, and 43% for nicotine patch, varencicline, and C-NRT, respectively.

RELATED REPORTS

Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

Combination treatment with varenicline and nicotine patch improves smoking cessation outcomes for concurrent alcohol users

Standard cytisine treatment for smoking cessation does not demonstrate noninferiority compared to standard varenicline treatment

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: smoking cessation
Previous Post

CT of the chest, abdomen, and pelvis demonstrates low diagnostic yield in low-velocity trauma

Next Post

Prenatal vitamin D supplementation does not reduce incidence of asthma

RelatedReports

Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Chronic Disease

Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

June 15, 2022
Secondhand smoke exposure counseling may be insufficient amongst cardiology inpatients
Chronic Disease

Combination treatment with varenicline and nicotine patch improves smoking cessation outcomes for concurrent alcohol users

April 7, 2022
Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Chronic Disease

Standard cytisine treatment for smoking cessation does not demonstrate noninferiority compared to standard varenicline treatment

July 7, 2021
Smoking during pregnancy associated with aerobic fitness of children
Chronic Disease

Nicotine replacement therapy for expectant fathers

June 27, 2021
Next Post
USPSTF finds insufficient evidence for screening for iron deficiency anemia during pregnancy

Prenatal vitamin D supplementation does not reduce incidence of asthma

RAS mutation linked with survival in metastatic colorectal cancer

2 Minute Medicine Rewind January 25, 2016

Nicotine biomarker predicts rates of smoking cessation in response to varenicline or nicotine patch

Free mailed nicotine patches may improve tobacco cessation

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Treatment of anal high-grade squamous intraepithelial lesions can reduce rates of progression to invasive anal cancer.
  • High tumour mutation burden in NSCLC associated with improved clinical outcomes of PD-L1 blockade across PD-L1 expression subgroups
  • Subsidization of supermarkets may help reduce obesity risk in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.